Navigation Links
Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that new preclinical research demonstrating a role in chronic inflammatory autoimmune disease for High Mobility Group Box-1 protein (HMGB1), a pro-inflammatory mediator and nuclear DNA-binding protein, will be published in the May 2007 issue of Nature Immunology. The publication demonstrates that HMGB1 is part of DNA complexes that can stimulate immune cells to produce potent inflammatory mediators, which in turn can contribute to the inflammatory pathology of autoimmune disease. The work adds to the growing body of literature regarding the pro-inflammatory activity of HMGB1 and indicates a potentially important role for this protein in chronic inflammatory disease as well as in severe, acute systemic inflammatory disease, such as sepsis.

"The work described in the Nature Immunology article provides important new insight into the mechanism by which HMGB1 exerts pro-inflammatory activity," said Gregory LaRosa, Ph.D., Critical Therapeutics' Vice President of Discovery Research. "The preclinical data suggest that HMGB1 may contribute to the disease pathology of lupus and supplement earlier research suggesting that a therapeutic antibody to HMGB1 may provide protection in chronic inflammatory disease. As we work in collaboration with MedImmune, Inc., to develop monoclonal antibodies (MAbs) directed towards HMGB1, this new information as to how HMGB1 provides a pro-inflammatory stimulus will help guide our efforts."

The collaboration with MedImmune and Critical Therapeutics is working to discover and develop novel therapeutics for both severe, acute inflammation, and for chronic allergic and autoimmune inflammatory diseases. The collaborative HMGB1 therapeutic antibody project is one of the key development efforts at Critical Therapeutics, and with MedImmune, has made progress towards the identificatio
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
3. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
4. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
5. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
10. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:3/18/2010)... March 18 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that the U.S. Patent ... the composition of matter patent for picoplatin as RE41209, ... 2010 . The reissue was applied for May ... , the USPTO released the "Issue Notification" for the ...
(Date:3/18/2010)... , March 18 ... Chief Executive Officer, Pfizer, was elected board ... of America (PhRMA) today at the trade ... Chief Executive Officer Christopher Viehbacher ... Directors, and John C. Lechleiter , ...
(Date:3/18/2010)... results in too much ammonia in the blood. , ... , , ... ... (Logo: ... ...
Breaking Medicine Technology:U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 2U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 3U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 4U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 2FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 3FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 4FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 5Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3Exposure to lead tobacco smoke raises risk of ADHD 10856 1Exposure to lead tobacco smoke raises risk of ADHD 10856 2Measuring and modeling blood flow in malaria 61892 1Measuring and modeling blood flow in malaria 61892 2
... after remission induction in previously untreated patients with follicular ... ... Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) announced today that the Company has ... to,discuss the possibility of filing a supplemental Biologics License,Application (sBLA) for use ...
... of Oxford Clinical Trial,Service Unit and Epidemiological Studies ... SEAS trial of ezetimibe should be,tested by reviewing ... trials of ezetimibe, and reporting on the overall ... drug,manufacturers., The two hypothesis-testing trials (SHARP and ...
Other Medicine Technology:CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 2CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 3CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 4Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 2Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 3
(Date:3/18/2010)... Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... ... WASHINGTON , March 18 Kids in New Jersey will take center stage in the fight against tobacco on March ...
(Date:3/18/2010)... ... , , ... ... ... New Hampshire will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide ...
(Date:3/18/2010)... President and CEO, Legacy(SM) , ... , , ... ... WASHINGTON , March ... ...
(Date:3/18/2010)... of U.S. medical students choosing internal medicine residencies ... significantly impact the shortage of primary care physicians. ... Program report, 2,722 U.S. seniors at medical schools ... 3.4 percent increase from 2,632 in 2009. The ... (2,660), 2007 (2,680), and 2006 (2,668). In comparison, ...
(Date:3/18/2010)... In its 21-year history, under the ... leaders, SRLA has trained more than 40,000 teenagers from ... area to complete the 26.2 mile Los Angeles Marathon. ... volunteer leaders will again participate in the LA Marathon. ... SRLA,s mission is to challenge at-risk secondary students to ...
Breaking Medicine News(10 mins):Health News:New Jersey Kids 'Kick Butts' on March 24 2Health News:New Jersey Kids 'Kick Butts' on March 24 3Health News:New Jersey Kids 'Kick Butts' on March 24 4Health News:New Jersey Kids 'Kick Butts' on March 24 5Health News:New Hampshire Kids 'Kick Butts' on March 24 2Health News:New Hampshire Kids 'Kick Butts' on March 24 3Health News:New Hampshire Kids 'Kick Butts' on March 24 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5Health News:Residency match results not encouraging for adults needing primary care 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 3
... by over 5 million people world wide, is held responsilble ... drug intake in UK. ,Pharmacovigilance statistics of MCA ... so called "yellow cards" during the period of January to ... explained that the main factor responsible for such an increase ...
... aspirin, acetaminophen(paracetamol) etc., is now identified to be the ... of Israeli researchers who treated 26 adolescents, found that ... was 28 each week, with 16 using pain medication ... that the headache symptoms decreased after 2 months.,Inspite of ...
... is a threeat to the globe as 95% of ... United Nations General Assembly Special Session on HIV/AIDS, physicians ... therapy that would cater the AIDS victims in developing ... without borders (commonly known as Medicines Sans Frontieres, or ...
... advertisements by the drug companies has prompted the doctors to ... news papers and magazines. American Medical Association's New Jersey delegate ... credibility especially if physician thinks an advertised drug isn't the ... added that ads have tuned into a competition "to see ...
... launched an oral treatment for smoking, called Zyban. ... first product aimed at stopping smoking and is available ... Mr. Kalyanasundaram, Director (Pharmaceuticals), Glaxo India Ltd, said the ... 7-12 weeks. ,In the first year of launch, ...
... kids is almost a nightmare to their respective parents, ... Researchers identified three factors that may increase a child's ... the disease that does not respond to commonly used ... before their first birthday which is also called symptomatic ...
Other Medicine News:
... primarily by 5-monodeioination of thyroxine (T4) in ... production occurs at a rate which is ... of T3 from the thyroid gland into ... to 80-100 micrograms/day for T4. In addition, ...
... Human Insulin-like growth factor binding protein-3 (IGFBP-3) is ... in postnatal serum, as a component of the ... IGFBP-3, a molecule of IGF-I or IGF-II and ... the actions of the IGFs. The molar concentration ...
... is a monomeric protein produced and stored ... GH is released from the pituitary into ... the regulatory control of hypothalamic somatostatin (SS) ... and frequency of GH release appears to ...
... (GH) is a monomeric protein produced and ... gland. GH is released from the pituitary ... under the regulatory control of hypothalamic somatostatin ... timing and frequency of GH release appears ...
Medicine Products: